Clinical practice guidelines for the management of non-functioning advanced GEP-NENs: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology (AIOM) in collaboration with the Italian Association for

Neuroendocrine neoplasms (NENs) of the gastroenteropancreatic (GEP) tract represent a rare and heterogeneous group of malignancies. They are distinguished into well-differentiated and poorly differentiated neoplasms, with clinical behavior ranging from relatively indolent to fast-growing, respectively. Surgery is the curative option for localized disease, especially in well-differentiated neoplasms, while various systemic therapies are approved and clinically available for advanced disease. However, considering the complexity of these malignancies, the choice of therapeutic strategy must take into account multiple factors, such as histological diagnosis, primary site, extent of disease, evolution features, functional status, patients and treatment characteristics, treatment availability, and safety profile. A multidisciplinary approach dedicated to NENs and conducted by experienced teams is therefore strongly recommended. Since 2013, the Italian Association of Medical Oncology (AIOM), in collaboration with the Italian Association for Neuroendocrine Tumors (ITANET), has produced guidelines using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach for assessing the certainty of evidence. This updated version (2024) summarized the main diagnostic and therapeutic decision-making processes on specific topics selected by a panel of experts from the AIOM, ITANET, and other national scientific societies with the aim of guiding clinicians in the diagnosis, treatment, and monitoring of patients with GEP-NENs. The integration of these guidelines into daily clinical practice is expected to improve patient care and drive the evolving landscape of GEP-NEN management.

Authors

Institutions

Publication Details

Journal
ESMO Open
Published
2025-11-01
DOI
https://doi.org/10.1016/j.esmoop.2025.105878
Citations
2
Primary Topic
Neuroendocrine Tumor Research Advances
Type
article
Field-Weighted Citation Impact
2.71

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical practice guidelines for the management of non-functioning advanced GEP-NENs: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology (AIOM) in collaboration with the Italian Association for

Riccardo De Robertis, Ivan Moschetti, Nadia Cremonini, E Bertani et al.
2 citations
ESMO Open
Neuroendocrine Tumor Research Advances
2.71
article

Clinical practice guidelines for the management of non-functioning advanced GEP-NENs: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology (AIOM) in collaboration with the Italian Association for

Riccardo De Robertis, Ivan Moschetti, Nadia Cremonini, E Bertani, Alfredo Berruti, Lorenzo Antonuzzo, Annamaria Colao, Saverio Cinieri, Massimo Milione, Filippo de Braud, Dario Giuffrida, Claudio Ricci, Antongiulio Faggiano, Salvatore Tafuto, Federica Perrone, Vincenza Granata, Angelo Tralongo, Valentina Ambrosini, Lisa Bodei, Nicola Fazio, Sara Massironi, Anna La Salvia, M. Di Maio, Guido Rindi, Sara Cingarlini, Valeria Ramundo, Michela Cinquini, Andrea Laghi, Roberta Modica, Davide Campana, Roberta Elisa Rossi, Marco Maccauro, D. Ravizza, Guido Bonomo, S Ortolani, Giuseppe Reimondo, Mauro Cives, Manuela Albertelli, Sara Pusceddu, Roberto Buzzoni, Luigi Funicelli, Chiara Maria Grana, Francesco Fiore, Francesco Panzuto, Annibale Versari, Maria Vittoria Davì, Maria Chiara Zatelli, Matteo Fassan, Diego Ferone, Giuseppe Pelosi, Toni Ibrahim, Maria Pia Brizzi, Sergio Baldari, Maurizio Castellano, Vito Amoroso, Giuseppe Badalamenti, Maria Rinzivillo, Massimo Falconi, Guido Alberto Massimo Tiberio, Jorgelina Coppa, Piero Ferollà, Stefano Partelli, Vincenzo Mazzaferro, Elettra Merola, Riccardo Casadei, Fabio Gelsomino, Emilio Bajetta, Gabriele Luppi, Paola Razzore, Veronica Andrea Fittipaldo, Francesca Spada, C.G. De Angelis, Riccardo Marconcini, Gabriele Capurso, Angelina Filice, Francesca Rizzo, Franco Grimaldi, Marco Barberis, M Papotti, R. Vigorito
article en
2 citations

Abstract

Neuroendocrine neoplasms (NENs) of the gastroenteropancreatic (GEP) tract represent a rare and heterogeneous group of malignancies. They are distinguished into well-differentiated and poorly differentiated neoplasms, with clinical behavior ranging from relatively indolent to fast-growing, respectively. Surgery is the curative option for localized disease, especially in well-differentiated neoplasms, while various systemic therapies are approved and clinically available for advanced disease. However, considering the complexity of these malignancies, the choice of therapeutic strategy must take into account multiple factors, such as histological diagnosis, primary site, extent of disease, evolution features, functional status, patients and treatment characteristics, treatment availability, and safety profile. A multidisciplinary approach dedicated to NENs and conducted by experienced teams is therefore strongly recommended. Since 2013, the Italian Association of Medical Oncology (AIOM), in collaboration with the Italian Association for Neuroendocrine Tumors (ITANET), has produced guidelines using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach for assessing the certainty of evidence. This updated version (2024) summarized the main diagnostic and therapeutic decision-making processes on specific topics selected by a panel of experts from the AIOM, ITANET, and other national scientific societies with the aim of guiding clinicians in the diagnosis, treatment, and monitoring of patients with GEP-NENs. The integration of these guidelines into daily clinical practice is expected to improve patient care and drive the evolving landscape of GEP-NEN management.

ESMO OpenVol. 10(11)
Università Cattolica del Sacro Cuore (IT), University of Messina (IT), University of Verona (IT), University of Modena and Reggio Emilia (IT), University of Udine (IT), Memorial Sloan Kettering Cancer Center (US), University of Padua (IT), Vita-Salute San Raffaele University (IT), University of Milan (IT), Mario Negri Institute for Pharmacological Research (IT), University of Ferrara (IT), Istituto Superiore di Sanità (IT), Agostino Gemelli University Polyclinic (IT), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT), Ospedale Santa Chiara (IT), Azienda Sanitaria Unità Locale di Reggio Emilia (IT), Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT), Ospedale di Spoleto (IT), Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT), Ospedale A. Perrino (IT), Urology Foundation (GB), Istituto Oncologico Veneto (IT), Azienda Ospedaliero-Universitaria Careggi (IT), Associazione Italiana Di Oncologia Medica (IT), Federico II University Hospital (IT), Azienda USL di Bologna (IT), National Cancer Institute (UA), Azienda Ospedaliera Sant'Andrea (IT), Fondazione Lanza (IT), A. O. Ordine Mauriziano di Torino (IT), National Cancer Institute (MY), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT), Ospedale Policlinico San Martino (IT), Ospedale San Luigi Gonzaga (IT), Villa Torri Hospital (IT), IRCCS Humanitas Research Hospital (IT), Azienda Ospedaliera Universitaria Pisana (IT), Regione Umbria, University of Florence (IT), University of Turin (IT), University of Bari Aldo Moro (IT), European Institute of Oncology (IT), University of Brescia (IT), University of Palermo (IT), University of Bologna (IT)
Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Associazione Italiana di Oncologia Medica, Boston Scientific Corporation, Moffitt Cancer Center, Les Laboratories Pierre Fabre, Incyte, Advanced Accelerator Applications, Astellas Pharma, European Society for Medical Oncology, Servier, Ipsen
Openalex Percentile: Top 8%
Neuroendocrine Tumor Research Advances
2.71
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.